ROWLAND LLOYD A 4
4 · CytomX Therapeutics, Inc. · Filed Feb 6, 2023
Insider Transaction Report
Form 4
ROWLAND LLOYD A
General Counsel
Transactions
- Award
Common Stock
2023-02-02+25,000→ 73,132 total - Award
Performance Stock Units (PSUs)
2023-02-02+75,000→ 75,000 total→ Common Stock (75,000 underlying) - Award
Stock Option (Right to Buy)
2023-02-02+75,000→ 75,000 totalExercise: $2.59Exp: 2033-02-01→ Common Stock (75,000 underlying)
Footnotes (5)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 47,500 RSUs.
- [F3]Includes 4,443 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022.
- [F4]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date.
- [F5]Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.